申请人:RIGEL PHARMACEUTICALS, INC.
公开号:US20130143875A1
公开(公告)日:2013-06-06
This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
本公开涉及一些化合物,这些化合物可用作蛋白激酶C(PKC)的抑制剂,并因此可用于治疗多种通过PKC的活性介导或维持的疾病和障碍。本公开还涉及包含这些化合物的制药组合物,使用这些化合物治疗各种疾病和障碍的方法,制备这些化合物的过程以及在这些过程中有用的中间体。